CORDIS
EU research results

CORDIS

English EN
International Randomized Study Comparing personalized, Risk-Stratified to Standard Breast Cancer Screening In Women Aged 40-70

International Randomized Study Comparing personalized, Risk-Stratified to Standard Breast Cancer Screening In Women Aged 40-70

Objective

MyPeBS addresses the crucial and timely question of the future of breast cancer screening in Europe. Indeed current standard mammographic screening, with entry stratified by age alone, has recently been largely questioned. Despite a demonstrated mean 20% reduction in breast cancer-specific mortality, together with reduction of late-stage disease in women older than 50, it is associated with potential harms including false positive recalls and over-diagnosis.
Individual breast cancer risk estimation, through models including clinical variables, mammographic breast density and more than 100 genetic polymorphisms, now has substantial clinical and scientific bases. Personalized screening strategies, based on individual risk levels, could potentially improve the individual benefit/harms ratio of screening (earlier cancer detection and less intensive treatments in high risk women, less false positives and over-diagnoses in low risk ones), and increase the cost-efficacy for health insurances.
MyPEBS will conduct an international randomized phase III trial to validate this hypothesis. It will primarily assess the ability of an individual risk-based screening strategy to be non-inferior, and possibly superior, to the standard of care screening, in reducing the cumulative incidence of stage II+ breast cancers. The trial, conducted in 5 countries (France, Italy, UK, Belgium and Israel) will include 85000 European women aged 40-70, all followed for 4 years. MyPEBS will also evaluate if an individual risk-based screening strategy, compared with the standard, reduces screening-related harms (unnecessary biopsies, overdiagnoses) in low-risk women, is overall at least as cost-effective as well as more accepted by women resulting in a larger screening coverage. After analyses of all components, the final objective of MyPEBS is to deliver recommendations for the best future breast cancer screening strategy in Europe.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNICANCER

Address

101 Rue De Tolbiac
75013 Paris

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 976 600

Participants (25)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUT GUSTAVE ROUSSY

France

EU Contribution

€ 540 750

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 310 622,50

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 545 431,25

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 394 312,50

QUEEN MARY UNIVERSITY OF LONDON

United Kingdom

EU Contribution

€ 103 940

PREDILIFE

France

EU Contribution

€ 245 000

UNIVERSITE PARIS 13

France

EU Contribution

€ 163 735

AZIENDA UNITA SANITARIA LOCALE DI REGGIO EMILIA

Italy

EU Contribution

€ 1 000 220

INSTITUT JULES BORDET

Belgium

EU Contribution

€ 660 000

LOUGHBOROUGH UNIVERSITY

United Kingdom

EU Contribution

€ 163 605

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

United States

EU Contribution

€ 25 000

AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO

Italy

EU Contribution

€ 593 400

AGENCE NATIONALE DE SANTE PUBLIQUE

France

EU Contribution

€ 12 500

INDEPENDENT CANCER PATIENTS' VOICE

United Kingdom

EU Contribution

€ 25 000

IM3D SPA

Italy

EU Contribution

€ 75 625

ASSOCIATION EUROPEENNE DES LIGUES CONTRE LE CANCER ASBL

Belgium

EU Contribution

€ 86 450

COLLEGE NATIONAL DES GENERALISTES ENSEIGNANTS

France

EU Contribution

€ 70 250

ASSUTA MEDICAL CENTERS LTD

Israel

EU Contribution

€ 985 000

ISTITUTO SCIENTIFICO ROMAGNOLO PERLO STUDIO E LA CURA DEI TUMORI SRL

Italy

EU Contribution

€ 250 000

ISTITUTO PER LO STUDIO E LA PREVENZIONE E LA RETE ONCOLOGICA

Italy

EU Contribution

€ 249 432,50

UNIVERSITE LYON 1 CLAUDE BERNARD

France

EU Contribution

€ 158 735

FONDATION ARC POUR LA RECHERCHE SUR LE CANCER

France

EU Contribution

€ 6 250

EONIX

Belgium

EU Contribution

€ 520 000

FONDATION JEAN DAUSSET CENTRE D'ETUDE DU POLYMORPHISME HUMAIN FONDATION

France

EU Contribution

€ 946 875

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 1 328 125

Project information

Grant agreement ID: 755394

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    31 December 2025

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 12 498 983,75

  • EU contribution

    € 12 436 858,75

Coordinated by:

UNICANCER

France